Novo Nordisk–Nanexa €1.165bn Deal: Why Novo Is Paying for Speed in Monthly GLP-1s
Novo Nordisk will pay up to €1.165 billion to license Nanexa’s PharmaShell coating. It gave up royalty points to buy speed. Even after doubling, Nanexa’s shares value the company at about a third of the pre-sales money.
Weekly injections made Novo Nordisk the most valuable company in Europe. Monthly ones will decide how much of that position it can recover. On Thursday evening the Danish drugmaker signed an exclusive global licence for Nanexa’s PharmaShell drug-delivery platform. The deal is worth up to €1.165 billion. Its structure looks like a company paying to close a gap: Novo put up money early and accepted a thin royalty because it is short of time and expects enormous volumes.
The terms are in Nanexa’s release. Up to €615 million comes as the upfront payment plus development and regulatory milestones. The remaining €550 million depends on sales, and Nanexa gets low single-digit royalties on global net sales. The licence covers up to five peptide programmes in obesity, type 2 diabetes and cardiometabolic disease, with monthly and quarterly dosing as the targets. The upfront figure was not broken out. Chief executive David Westberg would say only that the payments are “relatively front-loaded”.
The price makes sense next to the closest precedent. In June 2025 Eli Lilly licensed Camurus’s FluidCrystal depot technology for up to four incretin compounds. Camurus’s terms were up to $290 million in upfront, development and regulatory payments, $580 million in sales milestones and tiered mid-single-digit royalties. Novo is offering about $700 million before a single dose is sold, roughly two and a half times Lilly’s figure, for a technology with fewer years of human data. Its reward is a lower royalty.
The royalty swap is the signal. Say a monthly semaglutide product reaches $5 billion a year in sales, modest for this class. Every royalty point is then worth $50 million a year. Three points, about the gap between mid-single and low single digits, come to $150 million a year. On those numbers, the extra $400 million or so Novo paid before launch comes back in under three years of sales. A company expecting a niche product would have taken Lilly’s structure. Novo’s choice says it expects PharmaShell to sit inside franchise-sized drugs.
Novo is also in a hurry. At its capital markets day on Monday, chief executive Mike Doustdar set a target of more than five drugs with multi-blockbuster potential by 2030. The shares fell as much as 8% as investors decided the plan conceded too much ground to Lilly, according to CNBC’s report of the day. Doustdar admitted the company still had to rebuild the market’s trust. Chief scientific officer Martin Holst Lange has said Novo expects three or four once-monthly GLP-1 candidates to reach first human dosing this year. Pfizer’s monthly candidate has run into tolerability questions, the problem a slow-release coating is meant to solve.
The mechanism explains the price of a delivery platform. Semaglutide’s side effects cluster around peaks in blood concentration, and a monthly shot that releases its dose too quickly makes them worse. PharmaShell coats individual drug particles with an inorganic layer a few nanometres thick, laid down by atomic layer deposition, the same thin-film process used in semiconductor fabs. The coating controls how fast the drug escapes the depot under the skin. If it gives a flatter curve, Novo gets a monthly or quarterly product that patients tolerate as well as a weekly one. That matters in maintenance, where most obesity patients will spend years on treatment and where every missed injection hurts adherence.
The headline number is mostly air. Sales milestones and royalties depend on products that do not yet exist. Nanexa’s semaglutide formulations are preclinical, and its own liraglutide candidate, NEX-22, never became a commercial product. Moderna licensed the same platform in December 2025 for $3 million upfront against up to $500 million in milestones, a reminder that big-pharma headline values are cheap to print. That criticism applies to the €550 million back end, and the market has already written most of it off.
Nanexa has about 192 million shares. At around SEK 12 on Friday, up from SEK 5.93 at Thursday’s close, the company is worth roughly SEK 2.3 billion, or about €200 million. That is a third of the €615 million on offer before sales, and it gives nothing for the royalties or the Moderna option. A small Swedish company that had to raise money in dribbles now looks funded for years. Chairman Göran Ando said it would be able to take its own projects further before licensing them, which is where platform companies make real money.
There is a detail that says something about how Novo thinks. According to Realtid, Novo is already Nanexa’s largest shareholder, with 14.1%. It first bought in through a SEK 17.2 million directed issue at SEK 1.72 a share in December 2022, alongside an evaluation agreement. That means roughly one euro in seven of whatever Novo pays comes back to it as equity value. It also means Novo has watched PharmaShell data from the inside for almost four years. Buyers with that sort of access do not usually overpay for the first tranche.
Nanexa’s rerating is incomplete, and Novo’s cost is sensible. The risk to Nanexa holders is timing. Development milestones arrive only when Novo chooses to move a PharmaShell candidate into the clinic, and Novo’s priorities have changed more than once this year. For Novo shareholders, the deal matters less for the money than for what it says about the product plan. Novo appears to have concluded that its next generation of injectables needs a delivery technology it could not build fast enough in-house.
Two dates will test that. Nanexa’s third-quarter report on October 27 should show how much of the €615 million has already arrived as cash. We expect the first PharmaShell-formulated Novo candidate to enter human trials during 2027, which would trigger the first development milestone and give Nanexa shareholders the evidence that closes much of today’s discount. Lilly already has Camurus. Amgen and the rest of the monthly-dosing field will be looking for their own coating partner, and the Nanexa terms have just set the asking price.